PubRank

Drug news & perspectives (Drug News Perspect)

Journal PubWeight™ 383.26‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 The value of drug repositioning in the current pharmaceutical market. 2009 1.51
2 Macrophage migration inhibitory factor (MIF): a promising biomarker. 2010 1.48
3 Glutamate in CNS disorders as a target for drug development: an update. 1998 1.44
4 Lysyl oxidase as a potential therapeutic target. 2008 1.40
5 Hepatitis B virus transcription and replication. 2001 1.24
6 The antiviral activity of Toll-like receptor 7 and 7/8 agonists. 2008 1.23
7 Adenosine as a modulator of brain activity. 2007 1.22
8 The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. 2007 1.21
9 Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases. 2005 1.18
10 Biological effects of C1 inhibitor. 2004 1.17
11 The role of cathepsin K in normal bone resorption. 2004 1.16
12 Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. 2004 1.15
13 The antipsychotic potential of muscarinic allosteric modulation. 2010 1.15
14 Chemopreventive promise of targeting the Nrf2 pathway. 2007 1.13
15 The role of metabotropic glutamate receptor 5 in learning and memory processes. 2005 1.13
16 NF-kappaB and reperfusion injury. 2004 1.12
17 Caspase Activation in the Alzheimer's Disease Brain: Tortuous and Torturous. 2002 1.10
18 The role of X-box binding protein-1 in tumorigenicity. 2009 1.09
19 The roles of aldo-keto reductases in steroid hormone action. 2004 1.09
20 Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. 2008 1.08
21 JAK/STAT-dependent gene regulation by cytokines. 2005 1.08
22 Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. 2009 1.07
23 CTGF/Hcs24 as a multifunctional growth factor for fibroblasts, chondrocytes and vascular endothelial cells. 2003 1.07
24 Helicases as antiviral drug targets. 2003 1.07
25 Involvement of purinergic signaling in cardiovascular diseases. 2003 1.07
26 Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. 2009 1.06
27 Incretins and their analogues as new antidiabetic drugs. 2003 1.05
28 The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. 2004 1.05
29 Pandemic preparedness: toward a universal influenza vaccine. 2009 1.05
30 The Year's New Drugs & Biologics - 2009. 2010 1.04
31 Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. 2008 1.03
32 Heat shock protein-based novel immunotherapies. 2000 1.03
33 Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7) receptor and Pannexin-1. 2008 1.03
34 Targeting Wee1-like protein kinase to treat cancer. 2010 1.02
35 The complement system in schizophrenia. 2008 1.02
36 Protein kinase D and keratinocyte proliferation. 2004 1.02
37 Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. 2003 1.02
38 The role of CDK5/P25 formation/inhibition in neurodegeneration. 2006 1.00
39 Histone deacetylases as targets for the treatment of human neurodegenerative diseases. 2009 1.00
40 Herbal preparations as a source of hepatoprotective agents. 2001 1.00
41 Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. 2007 0.99
42 PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. 2010 0.99
43 Current status of gene therapy for muscle diseases. 2007 0.99
44 CXCR2--the receptor to hit? 2006 0.99
45 The corticotropin-releasing factor-hypocretin connection: implications in stress response and addiction. 2005 0.98
46 Chemopreventive functions of isothiocyanates. 2005 0.98
47 Angiogenesis and stroke. 1998 0.98
48 Therapeutic manipulations of peroxynitrite. 1998 0.98
49 The History of Thalidomide. 2002 0.98
50 The year's new drugs. 2001 0.98
Next 50